Jared Whitlock
Reporter
Phone: 858-634-4636 Extension: 3130
Recent Stories
Cos. Find Deals, Dollars at J.P. Morgan
BIOTECH: HL Buys, Sells; New Partnership Unveiled for Illumina
Debut Looks to Move Drug Manufacturing Forward
San Diego-Based Co. Closes $2.6 Million Seed Round
Neurocrine Deal Potentially Worth $412 Million
Company Would Pay Idorsia If It Licenses Drug
San Diego Companies Find Deals and Dollars at Health Conference
Two DNA sequencing companies raised more than $140 million combined, Daré Bioscience inked a potential commercialization deal worth up to $310 million, and Human Longevity sold its cancer division for $37 million, and separately, acquired a company.
Neurocrine Gains Option to License Epilepsy Drug; Deal Worth up to $412M
San Diego-based Neurocrine could buy the rights to yet another experimental epilepsy drug, per a recently announced agreement that could be worth up to $412 million.
DNA Sequencing Company Element Biosciences Raises $80.3M Round
Element Biosciences, another San Diego upstart that’s trying to make DNA technology more accessible, recently raised an $80.3 million round.
Tandem Diabetes Software Gets FDA OK
Closed-Loop System Controls Low and High Blood Sugar.
Epirium to Take on Muscle Diseases, Aging
BIOTECH: Company focused on mitochondria health, raises $85M round
Boosting ambitious plans, Epirium recently secured an $85 million Series A round, amid greater investment in muscle therapies.
Foundation Readies To Take On Ultra-Rare Diseases
Former Ionis CEO To Take Helm At Nonprofit.
Medical Device Cos. Applaud Tax Repeal
HEALTH: Excise Tax Was an ACA Financing Mechanism
A recently signed federal spending bill repealed a 2.3% excise tax on medical device makers that was scheduled to resume this month, a boon to San Diego’s medtech industry.
